Novartis Told to Revise Protocol, Justify Sample Size in ITU512 Clinical Trial Proposal
New Delhi: Novartis Healthcare Private Limited has been directed by the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organisation (CDSCO) to submit additional data and protocol clarifications for its proposed Phase I/II clinical study on ITU512, an investigational therapy for hemoglobin-related disorders.
The proposal was discussed during the 08th SEC (Haematology) meeting held on 15th July 2025 at CDSCO headquarters, New Delhi. Novartis presented Protocol No.CITU512A12101, Version 01, dated 29 July 2024.
ITU512 is believed to be an advanced therapeutic candidate potentially targeting sickle cell disease or β-thalassemia by modulating fetal hemoglobin levels. However, the SEC raised several scientific and protocol design concerns that require resolution before trial approval.
According to the committee, the primary endpoint must be clearly specified in terms of fetal hemoglobin (HbF) increase >15%, and this threshold must be scientifically justified based on prior studies, regulatory benchmarks, or clinical relevance. The panel also requested a justification for including patients with an absolute fetal hemoglobin percentage <15%.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.